Zagazig University, Faculty of Medicine
Zagazig, 44519, Egypt
NCT Number: NCT03404037
To assess the relationship between serum endostatin (ES) and Coronary artery calcification (CAC) in type 2 diabetic (T2DM) patients.
Looking for future studies?
Notify Me50 year–70 year
All sexes
Observational
Zagazig, 44519, Egypt
elevated serum endostatin levels were independently associated with increased risk, severity and progression of coronary artery calcification independent of traditional cardiovascular disease risk factors in T2DM subjects with known coronary artery disease. So, Measurement of serum ES levels can improve the diagnosis of coronary artery calcification and could be useful as a high sensitive marker for the presence and progression of atherosclerosis in T2DM patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients were between the ages of 50 and 70 years at enrollment.
Exclusion criteria
An oral (metoprolol 20 mg) was given to the patients with heart rates > 60 beats/minute and had no contraindications to beta-blockers, one hour before the scan. Sublingual nitroglycerin was given to all patients before CT examination. A 64-slice CT scanner (Sensation 64; Siemens Medical System, Germany) was used for imaging all subjects. All CT examinations were done during inspiratory breath holding.
Endostatin levels were measured using a sandwich ELISA kit according to the manufacturer's instructions endostatin ELISA kit (R&D Systems, Minneapolis, Minnesota, USA
Other names: Computed tomography
Time frame: 3-Months
Measurement of serum endostatin and Coronary artery calcification in type 2 diabetic patients patients and non-diabetic patients.
Zagazig University
Other Gov
Serum Endostatin Level as a Marker for Coronary Artery Calcification in Type 2 Diabetic Patients With Coronary Heart Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04726319
Adnexal Diseases, Arterial Occlusive Diseases
Toronto, Ontario, Canada
View Trial DetailsNCT04484259
Arterial Occlusive Diseases, Arteriosclerosis
Jacksonville, Florida, United States
View Trial DetailsNCT04523064
Acute Kidney Injury, Arterial Occlusive Diseases
São Paulo, Brazil
View Trial DetailsNCT03693560
Arterial Occlusive Diseases, Arteriosclerosis
Damanhūr, Egypt
View Trial Details